Status:

COMPLETED

Effect of Metformin on Carotid Atherosclerosis for Non-diabetic Patients With PsA (CAMPA Study)

Lead Sponsor:

Chinese University of Hong Kong

Conditions:

PsA (Psoriatic Arthritis)

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Background: Psoriatic arthritis (PsA) is a common chronic inflammatory disease with a prevalence up to 670 every 100,000 subjects. Patients with PsA has an increased risk of cardiovascular disease (CV...

Detailed Description

Psoriatic arthritis (PsA) is a common chronic inflammatory disease with a prevalence up to 670 every 100,000 subjects. Patients with PsA has an increased risk of cardiovascular disease (CVD) which is ...

Eligibility Criteria

Inclusion

  • fulfill the ClASsification criteria for Psoriatic ARthritis (CASPAR),
  • are over 18 years old,
  • have a Framingham Risk Score ≥ 10% (i.e. moderate to high CV risk) and
  • have carotid plague on previous ultrasound.

Exclusion

  • have prior therapy with metformin during the last 6 months;
  • have pre-existing diabetes as defined by the World Health Organization (WHO) criteria:
  • fasting plasma glucose values of ≥ 7.0 mmol/L,
  • 2-h post-load plasma glucose ≥ 11.1 mmol/L,
  • HbA1c ≥ 6.5% or
  • a random blood glucose ≥ 11.1 mmol/L);
  • have liver impairment: ALT more than or equal to 2.5×upper limits of normal;
  • have renal impairment: serum creatinine levels more than or equal to 135µmol/L in males and more than or equal to 110µmol/L in females;
  • have had ACS within the previous 3 months;
  • have New York Heart Association functional class 3 or 4 heart failure;
  • have uncontrolled angina;
  • have 70% or more stenosis on initial CCTA;
  • have clinically relevant current malignancy;
  • are pregnant; breastfeeding or of childbearing potential but unwilling to use adequate contraception;
  • are unable to give written informed consent;
  • patients with moderate to heavy alcohol intake.

Key Trial Info

Start Date :

August 30 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2025

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT05988684

Start Date

August 30 2023

End Date

September 30 2025

Last Update

November 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Chinese University of Hong Kong

Hong Kong, Hong Kong